Published in Gut on July 01, 2010
Noninvasive evaluation of NAFLD. Nat Rev Gastroenterol Hepatol (2013) 1.49
A new model using routinely available clinical parameters to predict significant liver fibrosis in chronic hepatitis B. PLoS One (2011) 1.16
Non-invasive assessment of liver fibrosis in chronic hepatitis C. Hepatol Int (2011) 1.15
Magnetic resonance elastography of the liver in patients status-post fontan procedure: feasibility and preliminary results. Congenit Heart Dis (2013) 1.08
KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol (2016) 1.07
Trends in the management and burden of alcoholic liver disease. J Hepatol (2015) 1.05
Acoustic radiation force impulse (ARFI) elastography for the noninvasive diagnosis of liver fibrosis in children. Pediatr Radiol (2012) 1.03
The role of serum biomarkers in predicting fibrosis progression in pediatric and adult hepatitis C virus chronic infection. PLoS One (2011) 1.02
MR relaxometry of the liver: significant elevation of T1 relaxation time in patients with liver cirrhosis. Eur Radiol (2012) 0.99
Pediatric liver MR elastography. Dig Dis Sci (2012) 0.98
The etiology, diagnosis and prevention of liver cirrhosis: part 1 of a series on liver cirrhosis. Dtsch Arztebl Int (2013) 0.95
Circulating CO3-610, a degradation product of collagen III, closely reflects liver collagen and portal pressure in rats with fibrosis. Fibrogenesis Tissue Repair (2011) 0.94
Novel algorithm for non-invasive assessment of fibrosis in NAFLD. PLoS One (2013) 0.93
Cross-vendor validation of liver magnetic resonance elastography. Abdom Imaging (2015) 0.93
Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy. PLoS One (2014) 0.92
Noninvasive assessment of portal hypertension in cirrhosis: liver stiffness and beyond. World J Gastroenterol (2014) 0.89
Hepatic venous pressure gradient: clinical use in chronic liver disease. Clin Mol Hepatol (2014) 0.87
Non-invasive diagnosis of hepatitis B virus-related cirrhosis. World J Gastroenterol (2014) 0.87
Non-invasive diagnosis of alcoholic liver disease. World J Gastroenterol (2014) 0.86
Effect of alcohol consumption on liver stiffness measured by transient elastography. World J Gastroenterol (2013) 0.85
Non-invasive diagnosis of liver fibrosis and cirrhosis. World J Gastroenterol (2015) 0.84
Transient elastography with the XL probe rapidly identifies patients with nonhepatic ascites. Hepat Med (2012) 0.84
Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies. Hepat Med (2011) 0.83
Staging of liver fibrosis or cirrhosis: The role of hepatic venous pressure gradient measurement. World J Hepatol (2015) 0.82
Serum apoptosis markers related to liver damage in chronic hepatitis C: sFas as a marker of advanced fibrosis in children and adults while M30 of severe steatosis only in children. PLoS One (2013) 0.82
Cost-utility analysis of nonalcoholic steatohepatitis screening. Eur Radiol (2015) 0.80
Direct comparison of the FibroScan XL and M probes for assessment of liver fibrosis in obese and nonobese patients. Hepat Med (2013) 0.80
Extracellular matrix and liver disease. Antioxid Redox Signal (2014) 0.80
Artificial neural network aided non-invasive grading evaluation of hepatic fibrosis by duplex ultrasonography. BMC Med Inform Decis Mak (2012) 0.80
Transient elastography for assessment of fibrosis in paediatric liver disease. Pediatr Radiol (2011) 0.80
Lack of a 5.9 kDa peptide C-terminal fragment of fibrinogen α chain precedes fibrosis progression in patients with liver disease. PLoS One (2014) 0.79
Liver stiffness measurement by transient elastography predicts early recovery from acute hepatitis. Gut (2010) 0.79
Current strategies for quantitating fibrosis in liver biopsy. Chin Med J (Engl) (2015) 0.78
Chronic hepatitis C virus infection: Serum biomarkers in predicting liver damage. World J Gastroenterol (2016) 0.77
Retrospective comparison of gradient recalled echo R2* and spin-echo R2 magnetic resonance analysis methods for estimating liver iron content in children and adolescents. Pediatr Radiol (2015) 0.77
Two classifiers based on serum peptide pattern for prediction of HBV-induced liver cirrhosis using MALDI-TOF MS. Biomed Res Int (2013) 0.76
Molecular magnetic resonance imaging of activated hepatic stellate cells with ultrasmall superparamagnetic iron oxide targeting integrin αvβ3 for staging liver fibrosis in rat model. Int J Nanomedicine (2016) 0.75
LIVER BIOPSY: IMPORTANCE OF SPECIMEN SIZE IN THE DIAGNOSIS AND STAGING OF CHRONIC VIRAL HEPATITIS. Rev Inst Med Trop Sao Paulo (2016) 0.75
Epigenetics and Liver Fibrosis. Cell Mol Gastroenterol Hepatol (2017) 0.75
Can elastometry be used for a better identification of cirrhosis? Clin Res Hepatol Gastroenterol (2011) 0.75
Systemic mastocytosis: a rare case of increased liver stiffness. Case Reports Hepatol (2012) 0.75
A novel non-invasive index using AFP and APTT is associated with liver fibrosis in patients with chronic hepatitis B infection: a retrospective cohort study. BMJ Open (2015) 0.75
Primary liver injury and delayed resolution of liver stiffness after alcohol detoxification in heavy drinkers with the PNPLA3 variant I148M. World J Hepatol (2016) 0.75
Sipa1l1 is an early biomarker of liver fibrosis in CCl4-treated rats. Biol Open (2016) 0.75
Evaluation of Transient Elastography, Acoustic Radiation Force Impulse Imaging (ARFI), and Enhanced Liver Function (ELF) Score for Detection of Fibrosis in Morbidly Obese Patients. PLoS One (2015) 0.75
Comparison of serological assessments in the diagnosis of liver fibrosis in bile duct ligation mice. Exp Biol Med (Maywood) (2017) 0.75
Assessment of Liver Fibrosis by Transient Elastography Should Be Done After Hemodialysis in End Stage Renal Disease Patients with Liver Disease. Dig Dis Sci (2017) 0.75
Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology (2004) 6.14
Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology (2008) 5.77
Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. Gastroenterology (2012) 3.86
Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol (2006) 3.59
Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology (2007) 3.39
Liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution. Hepatology (2013) 3.06
Measurement of spleen stiffness to evaluate portal hypertension and the presence of esophageal varices in patients with HCV-related cirrhosis. Gastroenterology (2012) 2.83
Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. Hepatology (2010) 2.68
Angiogenesis in liver disease. J Hepatol (2008) 2.31
Keratin 19: a key role player in the invasion of human hepatocellular carcinomas. Gut (2013) 2.10
StellaTUM: current consensus and discussion on pancreatic stellate cell research. Gut (2011) 2.07
gp120 modulates the biology of human hepatic stellate cells: a link between HIV infection and liver fibrogenesis. Gut (2009) 2.06
Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. Am J Pathol (2009) 1.87
A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions. Cancer Res (2005) 1.87
Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. N Engl J Med (2015) 1.84
Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology (2005) 1.81
Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. Gastroenterology (2008) 1.71
Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology (2008) 1.66
The chemokine CCL21 modulates lymphocyte recruitment and fibrosis in chronic hepatitis C. Gastroenterology (2003) 1.64
Beyond scoring: a modern interpretation of disease progression in chronic liver disease. Gut (2013) 1.63
Elastography for the non-invasive assessment of liver disease: limitations and future developments. Gut (2009) 1.60
Myofibroblast - like cells and liver fibrogenesis: Emerging concepts in a rapidly moving scenario. Mol Aspects Med (2007) 1.59
MARCKS actin-binding capacity mediates actin filament assembly during mitosis in human hepatic stellate cells. Am J Physiol Cell Physiol (2012) 1.58
Non invasive evaluation of portal hypertension using transient elastography. J Hepatol (2011) 1.42
Exposure to bacterial cell wall products triggers an inflammatory phenotype in hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol (2005) 1.33
Proangiogenic cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells. Am J Pathol (2007) 1.33
Transcriptional profiling reveals novel markers of liver fibrogenesis: gremlin and insulin-like growth factor-binding proteins. J Biol Chem (2006) 1.25
Binding of hepatitis C virus envelope protein E2 to CD81 up-regulates matrix metalloproteinase-2 in human hepatic stellate cells. J Biol Chem (2004) 1.24
Hepatitis C virus-replicating hepatocytes induce fibrogenic activation of hepatic stellate cells. Gastroenterology (2005) 1.24
Prevention of severe toxic liver injury and oxidative stress in MCP-1-deficient mice. J Hepatol (2006) 1.24
Non-invasive assessment of liver fibrosis: are we ready? Lancet (2010) 1.17
Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells. Am J Pathol (2006) 1.14
4-Hydroxynonenal as a selective pro-fibrogenic stimulus for activated human hepatic stellate cells. J Hepatol (2004) 1.14
Anti-fibrotic therapy: lost in translation? J Hepatol (2012) 1.12
Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. J Hepatol (2009) 1.10
Activation of p38(MAPK) mediates the angiostatic effect of the chemokine receptor CXCR3-B. Int J Biochem Cell Biol (2008) 1.07
Antifibrogenic effects of canrenone, an antialdosteronic drug, on human hepatic stellate cells. Gastroenterology (2003) 1.07
Up-regulated expression of fractalkine and its receptor CX3CR1 during liver injury in humans. J Hepatol (2002) 1.07
Adenosine monophosphate-activated protein kinase modulates the activated phenotype of hepatic stellate cells. Hepatology (2008) 1.06
A combination of the pediatric NAFLD fibrosis index and enhanced liver fibrosis test identifies children with fibrosis. Clin Gastroenterol Hepatol (2010) 1.05
Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Hepatol Int (2008) 1.04
Thiazolidinedione treatment inhibits bile duct proliferation and fibrosis in a rat model of chronic cholestasis. World J Gastroenterol (2005) 1.04
Expression of transmembrane 4 superfamily (TM4SF) proteins and their role in hepatic stellate cell motility and wound healing migration. J Hepatol (2002) 1.04
Hyaluronic acid predicts hepatic fibrosis in children with nonalcoholic fatty liver disease. Transl Res (2010) 1.02
Hepatic wound repair. Fibrogenesis Tissue Repair (2009) 1.01
Increased risk of hepatocellular carcinoma and liver cirrhosis in vinyl chloride workers: synergistic effect of occupational exposure with alcohol intake. Environ Health Perspect (2004) 0.99
Intracellular reactive oxygen species are required for directional migration of resident and bone marrow-derived hepatic pro-fibrogenic cells. J Hepatol (2010) 0.98
Performance of Doppler ultrasound in the prediction of severe portal hypertension in hepatitis C virus-related chronic liver disease. Liver Int (2007) 0.98
Combined paediatric NAFLD fibrosis index and transient elastography to predict clinically significant fibrosis in children with fatty liver disease. Liver Int (2012) 0.96
Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease. Ann Hepatol (2009) 0.96
The biphasic nature of hypoxia-induced directional migration of activated human hepatic stellate cells. J Pathol (2011) 0.95
Cell adhesion regulates platelet-derived growth factor-induced MAP kinase and PI-3 kinase activation in stellate cells. Hepatology (2002) 0.94
Myristoylated Alanine-Rich protein Kinase C Substrate (MARCKS) expression modulates the metastatic phenotype in human and murine colon carcinoma in vitro and in vivo. Cancer Lett (2013) 0.94
The metabolic syndrome and chronic liver disease. Curr Pharm Des (2014) 0.91
Curcumin limits the fibrogenic evolution of experimental steatohepatitis. Lab Invest (2009) 0.91
Reversal of liver fibrosis. Saudi J Gastroenterol (2009) 0.90
MARCKS is a downstream effector in platelet-derived growth factor-induced cell motility in activated human hepatic stellate cells. Exp Cell Res (2008) 0.90
Welcome to fibrogenesis & tissue repair. Fibrogenesis Tissue Repair (2008) 0.90
Evaluation of intracellular signalling pathways in response to insulin-like growth factor I in apoptotic-resistant activated human hepatic stellate cells. Fibrogenesis Tissue Repair (2009) 0.89
Role of the stromal-derived factor-1 (SDF-1)-CXCR4 axis in the interaction between hepatic stellate cells and cholangiocarcinoma. J Hepatol (2012) 0.89
Differential requirement of members of the MAPK family for CCL2 expression by hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol (2004) 0.88
Hepatic stellate cells stimulate HCC cell migration via laminin-5 production. Clin Sci (Lond) (2011) 0.88
Lack of CC chemokine ligand 2 differentially affects inflammation and fibrosis according to the genetic background in a murine model of steatohepatitis. Clin Sci (Lond) (2012) 0.87
Mammalian target of rapamycin mediates the angiogenic effects of leptin in human hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol (2011) 0.86
Diagnostic power of fibroscan in predicting liver fibrosis in nonalcoholic fatty liver disease. Hepatology (2009) 0.85
Intrabiliary metastasis from rectal cancer mimicking peripheral papillary-type cholangiocarcinoma. J Hepatol (2004) 0.84
Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C. Dig Liver Dis (2013) 0.84
Neuron-derived orphan receptor 1 promotes proliferation of quiescent hepatocytes. Gastroenterology (2013) 0.82
Paediatric non-alcoholic fatty liver disease. Gut (2010) 0.81
Liver stiffness correlates with methotrexate cumulative dose in patients with rheumatoid arthritis. Dig Liver Dis (2011) 0.81
Nuclear localization of TRK-A in liver cells. Histol Histopathol (2008) 0.80
Liver stiffness, a non-invasive marker of liver disease: a core study group report. Antivir Ther (2010) 0.78
Unraveling the spider web of hepatic stellate cell apoptosis. Gastroenterology (2009) 0.77
[Effects of alpha lipoic acid and pirfenidone on liver cells antioxidant modulation against oxidative damage]. Rev Med Chil (2014) 0.77
Alcoholic and non-alcoholic fatty liver in adolescents: a worrisome convergence. Alcohol Alcohol (2011) 0.76
Development and Regression of Cirrhosis. Dig Dis (2016) 0.75
Expanding the severity range of polytetrafluoroethylene-related hepatic outflow occlusion. Liver Int (2009) 0.75
Small diameter H-graft porta-caval shunt performed at different stages of liver disease. Hepatobiliary Pancreat Dis Int (2004) 0.75
EASL recognition awardee 2012: Professor Scott L. Friedman. J Hepatol (2012) 0.75
Hemodynamic derangement and cardiac dysfunction in cirrhosis. Ann Ital Med Int (2004) 0.75
What is new in the liver sinusoids? meeting report, 16th International Symposium on Cells of the Hepatic Sinusoid (ISCHS). Fibrogenesis Tissue Repair (2011) 0.75